home / stock / fblg / fblg news

FBLG News and Press, FibroBiologics Inc. From 09/10/25

Stock Information
Company Name: FibroBiologics Inc.
Stock Symbol: FBLG
Market: NASDAQ
Website: fibrobiologics.com
Menu
FBLG FBLG Quote FBLG Short FBLG News FBLG Articles FBLG Message Board
Get FBLG Alerts

News, Short Squeeze, Breakout and More Instantly...
FBLG - FibroBiologics Advances Bone Marrow Organoid Platform with Potential in Cancer and Immune Therapies

2025-09-10 12:31:23 ET FibroBiologics (NASDAQ: FBLG ), a biotech company developing fibroblast -based cell therapies, announced new progress with its bone marrow organoid platform, underscoring its potential in cancer research and immune-related disease treatment. The techno...
FBLG - FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

HOUSTON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...

FBLG - FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics reports 1H results

2025-07-31 17:59:52 ET More on FibroBiologics Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBiologics Financial information for FibroBiologics Read the full article on Seeking Alpha For further details see: ...
FBLG - FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics to Present at the Advanced Wound Care Summit USA

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
FBLG - FibroBiologics Confirms Ability to Manufacture CybroCell(TM) for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...
Previous 10 Next 10